Financials 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-10 pm EDT 5-day change 1st Jan Change
25.7 USD +0.23% Intraday chart for 4D Molecular Therapeutics, Inc. -2.58% +26.85%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,098 705.1 719.4 866.2 1,329 - -
Enterprise Value (EV) 1 821.4 457.3 505.9 617.1 826.8 925.3 1,129
P/E ratio -4.7 x -8.54 x -6.69 x -7.85 x -8.4 x -8.53 x -7.8 x
Yield - - - - - - -
Capitalization / Revenue 80.7 x 39.1 x 230 x 41.8 x 188 x 157 x 197 x
EV / Revenue 60.3 x 25.4 x 162 x 29.8 x 117 x 109 x 167 x
EV / EBITDA -14.9 x -6.55 x -4.7 x -5.68 x -5.33 x -4.03 x -3.93 x
EV / FCF -15.8 x - -5.15 x -7.85 x -4.89 x -5.44 x -6.12 x
FCF Yield -6.32% - -19.4% -12.7% -20.4% -18.4% -16.3%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 26,494 32,139 32,392 42,754 51,703 - -
Reference price 2 41.45 21.94 22.21 20.26 25.70 25.70 25.70
Announcement Date 3/25/21 3/28/22 3/15/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13.61 18.04 3.129 20.72 7.086 8.458 6.746
EBITDA 1 -55.22 -69.81 -107.6 -108.7 -155.2 -229.8 -287.1
EBIT 1 -56.66 -71.33 -110 -112.9 -157.4 -199.7 -231.4
Operating Margin -416.28% -395.46% -3,516.52% -544.65% -2,221.54% -2,361.07% -3,430.47%
Earnings before Tax (EBT) 1 - - -107.5 -100.8 -147.7 -136.3 -199.6
Net income 1 -56.69 -71.32 -107.5 -100.8 -150.4 -165.8 -199.6
Net margin -416.49% -395.37% -3,435.41% -486.59% -2,122.57% -1,960.55% -2,958.41%
EPS 2 -8.820 -2.570 -3.320 -2.580 -3.058 -3.014 -3.293
Free Cash Flow 1 -51.91 - -98.22 -78.56 -169 -170.1 -184.3
FCF margin -381.35% - -3,139.05% -379.11% -2,384.62% -2,011.47% -2,732.36%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 3/25/21 3/28/22 3/15/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.092 1.219 0.162 0.5 1.247 0.298 0.239 20.2 -0.019 - 1.207 1.212 1.218 0.5 0.5
EBITDA -24.37 - -27.96 - - -29.08 - - - - - - - - -
EBIT 1 -24.76 -26.39 -28.43 -26.5 -28.72 -30.11 -32.14 -13.97 -36.65 -38.14 -38.8 -39.5 -41.2 -46 -50
Operating Margin -26,917.39% -2,165.05% -17,546.91% -5,299% -2,303.13% -10,102.68% -13,446.03% -69.16% 192,905.26% - -3,214.05% -3,258% -3,381.48% -9,200% -10,000%
Earnings before Tax (EBT) 1 - - -28.09 -25.69 -27.38 -28.68 -29.62 -10.26 -32.28 -32.4 -36.13 -37.46 -39.82 - -
Net income 1 -25.08 -26.34 -28.09 -25.69 -27.38 -28.68 -29.62 -10.26 -32.28 -32.4 -38.4 -38.4 -44.3 - -
Net margin -27,264.13% -2,160.62% -17,337.04% -5,138.2% -2,195.59% -9,624.83% -12,391.63% -50.76% 169,910.53% - -3,180.91% -3,167.27% -3,635.92% - -
EPS 2 -0.8500 -0.8200 -0.8700 -0.7900 -0.8400 -0.8800 -0.7700 -0.2400 -0.7700 -0.6600 -0.7725 -0.8100 -0.8500 - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/28/22 5/12/22 8/11/22 11/8/22 3/15/23 5/10/23 8/9/23 11/9/23 2/29/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 277 248 214 249 502 403 200
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -51.9 - -98.2 -78.6 -169 -170 -184
ROE (net income / shareholders' equity) -61.8% -24.8% -39.1% -37.4% -44.6% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share 2 -7.920 -2.490 -2.680 -1.940 - - -
Capex 1 1 - 11.5 2.77 10 7.27 4.79
Capex / Sales 7.35% - 368.68% 13.37% 141.13% 85.91% 70.99%
Announcement Date 3/25/21 3/28/22 3/15/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.7 USD
Average target price
52.3 USD
Spread / Average Target
+103.50%
Consensus
  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. Financials 4D Molecular Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW